GeneFab的动态

Yesterday was a fantastic first day at #ASGCT2024! Our booth attracted many attendees from the gene and cell therapy research field. If you’re attending this week, stop by Booth #1856 to keep the conversation going! Come learn about our Agility Integra, a 21 CFR Part 11-compliant instrument, that can streamline your processes, provide precise sample analysis, and deliver reproducible results. #DYNEX #technology #ELISAautomation #21CFRPart11 #regulatorycompliance #drugdevelopment

Don’t forget to attend our sponsored session at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting on Friday, May 10 from 8-8:30 a.m. EDT. This session will cover how strategic collaborations between #CDMOs and #CROs are addressing industry challenges related to #viralvector production, leading to: - Improved AAV production titer with a significant reduction in cost of goods via high-throughput processes and analytical development - Direct scale-up from bench to 2,000L - Strategies for enhancing % full enrichment during downstream processing - Developing customer-centric analytics for viral vector characterization in development and GMP settings Learn more about this sponsored session here: https://spr.ly/6047jdT23

????? From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ???? #CellGeneTherapy #CGT #CellandGeneTherapies

????? From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ???? #CellGeneTherapy #CGT #CellandGeneTherapies

CAR-T sales from Gilead, Novartis, BMS and J&J are out, and they suggest a fast-growing marketplace *37% growth year-on-year*, totaling $3.7 bn, 2023 YE [vs $2.7 bn 2022 YE]. Whilst some of the individual products saw slight declines in revenue from 3Q to 4Q attributed to constraints with existing authorized treatment center and / or in-class and out-of-class competition, the overall sentiment is one of growth! No surprise that cell therapy has seen a "renaissance" in the past months, with growing interest from investors and uptick in deal making More details in my Cell & Gene weekly newsletter -> https://lnkd.in/eN_DZDHC

????? From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ???? #CellGeneTherapy #CGT #CellandGeneTherapies

Lack of regulatory guidance is a bioanalytical concern in developing AAV therapies. How do you assess the effectiveness of your current bioanalytical support services in meeting regulatory requirements? Gain insights from Boris Gorovits in our latest interview: Shaping gene and cell therapy innovations with bioanalysis >>> https://hubs.ly/Q02YGYtT0

Heading to ASGCT in Baltimore? Come get your groove on at booth #730 or check out our talk to learn how Stunner and Leprechaun can help you bust through bottlenecks in your gene and cell therapy workflows! #ASGCT2024!

????? From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ???? #CellGeneTherapy #CGT #CellandGeneTherapies

Biocom California recently invited Sapient to contribute an article for its Lifelines Magazine edition focused on innovations in #genetherapy and #celltherapy. https://bit.ly/3V6gqd4 While cell- and gene-based treatments are advancing rapidly, spurred by a landmark year of FDA approvals, their development is not without challenges. We discuss how #multiomics for gene and cell therapy can deliver the novel insights needed to realize the incredible therapeutic potential represented in these pipelines today: https://bit.ly/3V6gqd4